UNSPSC 51392901: Picumeterol

This classification denotes a beta-adrenergic agonist with the molecular formula C21H29CL2N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 86WEQ311WF chemically known as benzenemethanol, 4-amino-3,5-dichloro-.alpha.-(((6-(2-(2-pyridinyl)ethoxy)hexyl)amino)methyl)-, (r)- but generally known as picumeterol, which bears US NIH Compound Identifier 131251. European Medicines Agency schedules Picumeterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09822MIG.

UNSPSC 51392901 Picumeterol is a Commodity code with minimal recent state and local procurement activity directly aligned to its nominal scope. The two recent opportunities tagged under this code address pharmaceutical procurement broadly — naloxone and drug deactivation systems in one case, and direct-to-manufacturer pharmacy benefit programs in the other — but neither involves picumeterol specifically as a product line. State and local health and human services agencies are the primary issuing bodies appearing in recent solicitations under this code, suggesting it is used as a catch-all classification for pharmaceutical products and pharmacy services rather than as a precise commodity identifier.

Activity is geographically sparse, with recent opportunities limited to Florida and Texas. Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding with quarterly deliveries to the Seminole County Community Health Building in Sanford, with a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information about direct contracting between state pharmacy benefit programs and pharmaceutical manufacturers. The mismatch between the picumeterol code name and the actual pharmaceutical procurement activity suggests that this UNSPSC classification may not be a reliable predictor of opportunity flow in state and local markets; firms pursuing pharmaceutical or pharmacy benefit work should monitor broader health services solicitations rather than rely solely on this code.